Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
relacorilant + enzalutamide
- Development stage
- Unknown
- Lead developer
- Corcept Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Relacorilant + enzalutamide is an investigational combination therapy comprising the selective glucocorticoid receptor modulator (SGRM) relacorilant and the androgen receptor (AR) inhibitor enzalutamide. Developed by Corcept Therapeutics in collaboration with the University of Chicago, this combination is primarily being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapeutic rationale is based on the observation that glucocorticoid receptor (GR) signaling can compensate for inhibited AR signaling, providing a survival pathway for cancer cells and contributing to enzalutamide resistance. By concurrently inhibiting both the GR and AR, the combination aims to block these escape mechanisms and enhance anti-tumor activity.
- Other names
- relacorilant and enzalutamideCORT125134 + enzalutamideCORT125134 + MDV3100
02
Targets
GR (Glucocorticoid receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on relacorilant + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on relacorilant + enzalutamide.